Bluejay Therapeutics’ Post

𝐍𝐮𝐫𝐢𝐱 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐬 𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐃𝐚𝐭𝐚 𝐟𝐨𝐫 𝐍𝐗-𝟓𝟗𝟒𝟖 𝐚𝐭 𝐈𝐖𝐖𝐌-𝟏𝟐 Nurix Therapeutics, Inc. (Nasdaq: NRIX) Nurix Therapeutics shared encouraging clinical results from its Phase 1a/1b trial of NX-5948 at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM-12) in Prague. NX-5948, a brain-penetrant BTK degrader, showed promising outcomes in patients with relapsed/refractory Waldenstrom’s macroglobulinemia (WM). Among 9 evaluable patients, 77.8% achieved an objective response, with stable disease observed in the remaining 22.2%. Responses occurred within 8 weeks, with some patients continuing treatment beyond one year. These results highlight the potential of NX-5948, including its ability to target rare cases with central nervous system involvement like Bing-Neel syndrome. #Biopharma #CancerTreatment #WaldenstromsMacroglobulinemia #BTKDegrader #IWWM12 #Nurix

Read the inspiring story of Rachael A Hagan and NephroDI Therapeutics, Inc., a biotech startup developing a novel treatment for a rare kidney disorder called Nephrogenic Diabetes Insipidus (NDI) and recent addition to our, Sound Bioventures, portfolio. #NDI #nephrology #drugdiscovery #biotech #startup

Pliant Therapeutics Highlights the P-II Results of Bexotegrast 320mg to Treat Primary Sclerosing Cholangitis and Suspected Liver Fibrosis #plianttherapeutics #bexotegrast #primarysclerosingcholangitis #suspectedliverfibrosis #clinicaltrial #phase2 #integrispsc #safety #tolerability #efficacy #mriimaging #fibrosismarkers

Check our latest review about Toll-like receptor signalling as a cannabinoid target. Melody Cui Sun, Almudena Otálora Alcaraz , Jack Prenderville, Eric Downer Read article here: https://lnkd.in/eRyWC_ER There is evidence that TLR dysregulation can contribute to disease pathogenesis. Additionally, cannabinoids can cross-talk with TLRs signalling. This review highlights evidence that cannabinoids are key regulators of TLR signalling and their potential as anti-inflammatory therapeutics.

Aileron Therapeutics Reveals Cohort 1 Data from the P-Ib Clinical Evaluation of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF) #ailerontherapeutics #lti03 #idiopathicpulmonaryfibrosis #clinicaltrial #phase1 #safety #efficacy #tolerability #inflammation #fibrosis #ipf

In one of the most highly anticipated clinical trial readouts this year, an #RNA silencing treatment developed by Alnylam Pharmaceuticals reduced the risk of death, heart-related hospital visits and hospitalizations by 28% compared to placebo in patients with a heart muscle disease. The results, announced Monday, pave the way for Alnylam’s therapy vutrisiran to become the first RNA silencing therapy on the market for ATTR amyloidosis with cardiomyopathy, a condition in which misfolded proteins build up in the heart and can result in heart failure. If approved, Alnylam could enter a multibillion-dollar market currently dominated by Pfizer. #clinicaltrials #clinicalresults #readout #RNAsilencing #heartmuscledisease #vutrisiran #heartdisease #cardiology #cardio #ATTRcardiomyopathy #patients #PhaseIII #clinicaldata

🚀 Dive into the Blockbuster Journey of Tepezza! 🌟 Discover how Horizon Therapeutics transformed thyroid eye disease treatment with Tepezza, setting a new standard in ophthalmic care. Don't miss this valuable case study, which provides launch and market entry lessons for the biopharma industry! Watch now: https://lnkd.in/dcEfA4tw #Tepezza #HorizonTherapeutics #OphthalmicBlockbuster #RareDisease #ThyroidEyeDisease #TepezzaCaseStudy #Pharma #HealthcareInnovation

#ASCO24 #BreastCancer The DESTINY-Breast07 study serves as a prelude to DESTINY-Breast09. T-Dxd monotherapy and the combination of T-Dxd with pertuzumab have shown promising efficacy. Except for a higher incidence of grade 2 diarrhea with T-Dxd + pertuzumab compared to T-Dxd alone, the safety profile was favorable. The combination also demonstrated excellent ORR, especially CR, 12-month PFS, and efficacy regardless of disease and HR status. Question 1: How will Roche utilize the HER2 TKI ZN-1041 acquired from Zion Pharma Llc? Is Roche potentially entering the HER2+ mBC market where T-Dxd has already established a strong presence? At AACR23, AstraZeneca presented exciting findings. In HER2-low cell lines, treatment with irreversible inhibitors such as neratinib or afatinib resulted in more than a 50% reduction in surface HER2 levels due to increased internalization. Conversely, treatment with reversible inhibitors like lapatinib or tucatinib resulted in a 13-35% increase in surface HER2 levels. Irreversible HER2-TKIs can promote HER2 internalization, potentially enhancing T-Dxd binding to HER2. It's like getting on a moving carriage. https://lnkd.in/gsypamuy Question 2: The stratification factors for DESTINY-Breast07 include PD-L1 status, and although it has yet to be previously announced, Module 1 includes T-Dxd + Durvalumab. We've seen data on the T-Dxd + Durvalumab combination from the BEGONIA trial but not in HER2+ mBC. https://lnkd.in/gVxW9vDN

Cardiol Therapeutics, a leader in developing anti-inflammatory and anti-fibrotic therapies for 𝐡𝐞𝐚𝐫𝐭 𝐝𝐢𝐬𝐞𝐚𝐬𝐞, has sold 9.7 million shares for $15.5 𝐦𝐢𝐥𝐥𝐢𝐨𝐧. These funds will support the clinical development of 𝐂𝐚𝐫𝐝𝐢𝐨𝐥𝐑𝐱, a promising treatment for 𝐫𝐞𝐜𝐮𝐫𝐫𝐞𝐧𝐭 𝐩𝐞𝐫𝐢𝐜𝐚𝐫𝐝𝐢𝐭𝐢𝐬 - a condition marked by inflammation around the heart. As heart disease continues to be a growing global health challenge, it's vital to support innovative companies like Cardiol Therapeutics in the development of novel, safe and effective treatments. 🔗 Learn more here: https://lnkd.in/gunDfQez #CardiolTherapeutics #ClinicalTrials #HeartHealth #Biotech #HealthcareInnovation #CardiolRx #Pericarditis #InflammationTherapy #InvestInHealth #HeartDiseaseResearch #DrugDevelopment

Cardiol Therapeutics Inc. (@cardiolrx) recently announced positive topline results from its Phase II MAvERIC-Pilot study, investigating the impact of CardiolRx™ on patients with symptomatic recurrent pericarditis. The study enrolled 27 adult patients across prominent clinical sites in the U.S., including the Mayo Clinic, Cleveland Clinic, and Massachusetts General Hospital. The results demonstrated a significant reduction in pericarditis pain, with the mean pain score dropping from 5.8 at baseline to 2.1 (64%) after eight weeks of treatment. Additionally, 80% of patients with elevated baseline C-reactive protein (CRP) levels achieved normalization, indicating a substantial reduction in inflammation. 'We are delighted to share the exceptional primary endpoint data from the MAvERIC-Pilot study, which demonstrated that oral administration of our small molecule CardiolRx™ led to marked reductions in pericarditis pain and inflammation,' said David Elsley, President & CEO of Cardiol Therapeutics. With an estimated 38,000 patients in the U.S. experiencing recurrent pericarditis annually, the need for effective treatments is critical. Cardiol Therapeutics aims to provide an accessible and non-immunosuppressive therapeutic option, potentially surpassing existing therapies. The positive results set the stage for a forthcoming Phase III trial. #RecurrentPericarditis #CardiolTherapeutics #CardiolRx #ClinicalTrials #Biotechnology #Healthcare @cardiolrx @mayoclinic @clevelandclinic @massgeneralnews